Aim: Peripheral arterial disease (PAD) is a common cause of cardiovascular morbidity and an independent predictor of cardiovascular mortality. However, little is known about the genetic basis of PAD. To elucidate this, we performed a two-staged genome-wide association study in Japanese individuals. Methods: We initially tested 222,285 single-nucleotide polymorphisms (SNPs). After the first screening in a panel of 195 PAD cases and 1,358 controls, 2,696 SNPs (1.2%) were further genotyped in the second screening using another panel of 699 PAD cases and 1540 controls. In both screenings, controls were subjects affected with some diseases other than PAD. Results: When analyzed in the combined panel, the strongest signal of PAD association was observed at rs1902341 in the intron of OSBPL10 (p 4.7E-7 for trend test; OR 1.31, 95% CI 1.18 − 1.46). Also, PAD was modestly associated at several other loci such as rs2554503 in CSMD1 (p 5.7E-5; OR 1.32, 95% CI 1.15 − 1.51) or rs235243 in VSP13D (p 0.04; OR 1.18, 95% CI 1.01 − 1.37). Conclusion: Our genome-wide exploration identified suggestive evidence of PAD association at the OSBPL10 locus. Because the association has not reached a genome-wide significant level, further replication study is warranted for verification in the Japanese population.
Introduction
Peripheral arterial disease (PAD) is characterized by pain, ulceration and necrosis of the lower extremi-jects over the age of 70 years, the prevalence of PAD is over 25% in North America and Europe 5) . Despite its prevalence and the high social cost attributed to PAD 6) , the genetic basis of PAD and the factors that determine its responsiveness to treatment are yet to be understood. There are no genetic tests available that reliably identify the subset of subjects carrying inherited risk factors for developing PAD on a large scale 7) ; however, three family studies to date have reported estimates of heritability of PAD and thus its heritability could be suggested [8] [9] [10] . A logical next step is to perform a more comprehensive and unbiased scan of variations in all genes or in the entire genome using what is commonly referred to as a genome-wide association study (GWAS). Thus, the aim of this study was to identify PAD-susceptible genes through GWAS of SNPs.
Methods

Study Participants
BioBank Japan: For the GWAS, we selected casecontrol samples (cases 1 and 2, controls 1 and 2) from subjects enrolled in BioBank Japan. The subjects were recruited from several medical institutes in Japan, including Fukujuji Hospital, Iizuka Hospital, Iwate Medical University School of Medicine, Juntendo University, National Hospital Organization Osaka National Hospital, Nihon University, Nippon Medical School, Osaka Medical Center for Cancer and Cardiovascular Diseases, and Shiga University of Medical Science, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokushukai Hospitals and Tokyo Metropolitan Geriatric Hospital.
We selected peripheral arterial disease cases from the individuals registered. We defined PAD as those with either stenosis on angiography of the lower limbs or with ABI fulfilling the diagnostic criteria among patients complaining of symptoms such as intermittent claudication or pain in the lower limbs. (case 1, n 195; case 2, n 699). Control groups were 1,358 (control 1) and 1,540 individuals (control 2) registered as subjects without apparent clinical symptoms of PAD and having diseases other than PAD, including bronchial asthma, myocardial infarction, breast cancer, Basedow's disease, cerebral infarction, cerebral aneurysm, osteoporosis, heart failure, unstable angina, pollinosis, type 2 diabetes, emphysema, atopic dermatitis, stomach cancer or liver cirrhosis. The control subject group includes 194 cases of diabetes, 194 of cerebral infarction (control 1), 188 of myocardial infarction, and 189 of unstable angina (control 2).
All participants provided written informed consent. The protocol was approved by the ethics committee of Osaka University and of each participating institution.
SNP Genotyping Methods
Using standard protocols, we extracted genomic DNA from peripheral blood leukocytes. In the first stage, we genotyped 268,068 SNPs from autosomal chromosomes; these SNPs were selected as tagging SNPs for the Japanese population from the JSNP 11) or HapMap database 12) using high-density oligonucleotide arrays (Perlegen Sciences) as described previously. SNPs having a call rate 90% and no extreme departure from Hardy-Weinberg Equilibrium (p 10 6 ) were passed and used for the association study. In the second study, genotyping was conducted using the multiplex-PCR invader assay 13) for PAD subjects and high-density oligonucleotide arrays (Perlegen Sciences) for control subjects. In the multiplex-PCR invader assay, SNPs having a call rate 85% were passed and used for the association study. Regarding the success rates of the multiplex-PCR invader assay 90% agreement existed between the results of genotyping and direct sequencing.
Statistical Analysis
Statistical methods for determining associations and calculating LD coefficients (r 2 ) have been described previously 14) . We performed the HWE test according to a method previously described 15) . The cut-off value for the HWE test in control groups was 0.000001 for the first stage and 0.01 for the second stage; SNPs with p values less than the cut-off values of the HWE test were excluded from analysis. We analyzed the differences between case and control groups with respect to the genotype distribution and allele frequency in genome-wide screening (first or second stage) by Fisher's exact test using dominant, recessive and allelic models with autosomal SNPs.
Results
Genome-Wide Association Study
To identify variants associated with susceptibility to PAD, we performed a genome-wide case-control study in 195 individuals with PAD (case 1) and 1,358 controls (control 1) collected from the BioBank Japan, and genotyped 268,068 SNPs, which covered approximately 56% of common SNPs in Japanese (flow diagram of study is shown in (Fig. 1A, 1B, 1C) . Baseline characteristics for the populations in this study are shown in 2006), and the first (X axis) and 2nd (Y axis) principal components were plotted. Japanese samples were clearly plotted in a single cluster, except for one sample. One subject in the 1st test was halfway between Japanese and CEU. The Japanese cluster and Chinese cluster were very close, although it seems that some differences exist between these two populations. , OR 1.28, 95%CI 1.14 − 1.44) after removing atherosclerotic disease subjects (n 765) from the controls. ond screening are shown in Table 3 .
Through out this analysis, we identified several candidate SNPs, including an SNP with the lowest p value, located on chromosome 3p22.3. The combined p values of these SNPs located on chromosome 3p22.3 were 4.7 10 7 (rs1902341), 2.7 10 6 (rs6779621), and 2.1 10 5 (rs2168422), 2.7 10 5 (rs2045298), respectively, some of which were close to the p value threshold of 5 10 7 to 5 10 8 , which is necessary in the setting of GWAS ( Table 3) .
Since the control subject group included cases of diabetes, cerebral infarction, myocardial infarction, and unstable angina, we performed additional association analysis for three SNPs (rs1902341, rs6779621, rs2168422) using control subjects without patients with these atherosclerotic diseases. Allele frequency in the control group changed little after subtracting these subjects. The odds ratios of these 3 SNPs without these subjects were also statistically significant (rs6779621, OR 1.31 (95% CI, 1.16 − 1.48); rs2168422, OR 1.28 (95% CI, 1.14 − 1.44); rs1902341, OR 1.32 (95% CI, 1.18 − 1.47)). We further performed age-and sex-matched re-analysis of stage 2 samples in 645 individuals with PAD and 645 controls. These three SNPs were still associated (p 0.009, 0.012, 0.018, respectively).
LD Block
We subsequently attempted to construct a linkage-disequilibrium (LD) block at chromosome 3p22.3 to define the region showing a strong association with PAD. As shown in Fig. 2 , significant SNPs were located within intron 5 of OSBPL10 (oxysterol binding protein like 10). Since the total length of the OSBPL10 gene is about 300 kb, and SNPs on both sides of the 3 SNPs have high p values ( Table 4) , it is unlikely that they influence adjacent genes other than OSBPL10.
Discussion
Identification of PAD susceptibility genes could have an important impact on the diagnosis and treatment of this disease. In this study, we utilized the GWAS approach and identified a susceptible gene for PAD, OSBPL10.
Oxisterol binding protein (OSBP) has been identified in eukaryotic species from yeast to humans 16) . The human OSBP family consists of 12 members. OSBP family proteins have an oxysterol binding domain, which binds oxysterol, and a PH domain, which attaches to non-ER membranes via binding of phosphatidylinositol 17, 18) . By binding oxysterol or cholesterol, they cause conformational change, and induce signal transduction to regulate cholesterol homeostasis.
In this study, we found that SNPs of OSBPL10 were associated with PAD. Recently, Perttila et al. reported that OSBPL10 is associated with a high triglyceride trait in Finnish subjects and regulates cellular lipid metabolism 19) . Because dyslipidemia is one of the risk factors of PAD, it can be speculated that OSBPL10 associates with PAD through the dysregulation of serum lipid homeostasis. OSBPL10 may be associated with cholesterol metabolism or transport, suggesting that it may be associated with coronary artery disease and/or ischemic stroke. However, the Table 2 (set 1 set 2) for rs6779621, rs2168422 and rs1902341 and from Table  3 (set 1) for other SNPs. function of oxysterol binding proteins and the OSBPL10 gene have not been clarified yet, and no study has examined the association with coronary artery disease and/or ischemic stroke.
In the present study, several genes other than OSBPL10 that showed borderline association were identified ( Table 3) . SNP in the CSMD1 gene (rs2554503) showed a relatively small p value (p 5. 7 10 5 ). CSMD1 is a complement regulatory protein that blocks the classical but not alternate complement pathway 20) and is associated with Kawasaki disease 21) . Interestingly, recently, it was reported that SNPs in the CSMD1 gene are also associated with metabolic syndrome 22) and hypertension 23) . SNPs in VPS13D genes showed high combined p values (p 0.04 0.05). This gene encodes a protein belonging to the vacuolar-protein-sorting-13 gene family. In yeast, vacuolar-protein-sorting-13 proteins are involved in trafficking membrane proteins between the trans-Golgi network and the prevacuolar compartment. It was reported that in wild-type yeast, insulin is ultimately delivered to the vacuole, whereas vps mutants secrete primarily unprocessed insulin-containing fusion protein 24) ; however, the function of human genes (VPS13A-D) has not been analyzed yet 25) . Some SNPs in intergenic regions also showed relatively small p values, such as rs2359536 (p 1. 5 10 6 ). At present, the function and significance of these regions are unknown. Further studies are necessary to confirm the significance of these associations.
PAD is a complex trait whose development is probably modified to some degree by unchanged genetic determinants that are independent of traditional risk factors for atherosclerosis. Although we applied the GWAS approach to PAD, the large numbers of association tests that result from GWAS scans require that an even lower probability value threshold be used to identify promising associations between variants and disease. It has been reported that a p value threshold of 5 10 7 to 5 10 8 is necessary in the setting of GWAS 26, 27) . This study is still in the screening stage and needs a replication study using an independent panel of cases (PAD patients) and controls in the future. To date, several genes susceptible to PAD have been reported in a case-control study with sample sizes ranging from ~100 to 1300 subjects 7) , but we could not confirm these genes as candidate genes in our study. Thus, we speculate that our genome-wide association study still cannot cover all the genes for PAD. Further studies are necessary to elucidate the underlying molecular mechanism of the genes and gene polymorphisms conferring susceptibility to PAD.
In conclusion, our genome-wide exploration identified evidence suggestive of PAD association at the OSBPL10 locus. 
